Psychometric properties of the Friedreich Ataxia Rating Scale.
Journal
Neurology. Genetics
ISSN: 2376-7839
Titre abrégé: Neurol Genet
Pays: United States
ID NLM: 101671068
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
07
06
2019
accepted:
23
09
2019
entrez:
12
2
2020
pubmed:
12
2
2020
medline:
12
2
2020
Statut:
epublish
Résumé
To investigate the psychometric properties of the Friedreich Ataxia Rating Scale neurologic examination (FARSn) and its subscores, as well as the influence of the modifications resulting in the now widely used modified FARS (mFARS) examination. Based on cross-sectional FARS data from the FA-Clinical Outcome Measures cohort, we conducted correlation-based psychometric analyses to investigate the interplay of items and subscores within the FARSn/mFARS constructs. The results provide support for both the FARSn and the mFARS constructs, as well as individually for their upper limb and lower limb coordination components. The omission of the peripheral nervous system subscore (D) and 2 items of the bulbar subscore (A) in the mFARS strengthens the overall construct compared with the complete FARS. A correlation-based psychometric analysis of the neurologic FARSn score justifies the overall validity of the scale. In addition, omission of items of limited functional significance as created in the mFARS improves the features of the measures. Such information is crucial to the ongoing application of the mFARS in natural history studies and clinical trials. Additional analyses of longitudinal changes will be necessary to fully ascertain its utility, especially in nonambulant patients.
Identifiants
pubmed: 32042904
doi: 10.1212/NXG.0000000000000371
pii: NG2019011189
pmc: PMC6927357
doi:
Types de publication
Journal Article
Langues
eng
Pagination
371Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Brain. 2013 Jan;136(Pt 1):259-68
pubmed: 23365101
Mov Disord. 2012 Jan;27(1):135-8
pubmed: 22076850
J Neurol Neurosurg Psychiatry. 2007 Apr;78(4):411-3
pubmed: 17056635
Lancet Neurol. 2015 Feb;14(2):174-82
pubmed: 25566998
Lancet Neurol. 2016 Dec;15(13):1346-1354
pubmed: 27839651
Ann Clin Transl Neurol. 2019 Feb 27;6(3):546-553
pubmed: 30911578
J Neuropathol Exp Neurol. 2013 Feb;72(2):78-90
pubmed: 23334592
Gait Posture. 2018 Mar;61:149-162
pubmed: 29351857
Neurology. 2005 Apr 12;64(7):1261-2
pubmed: 15824358
J Neurol. 2009 Mar;256 Suppl 1:36-41
pubmed: 19283349
J Neurol Sci. 1997 Feb 12;145(2):205-11
pubmed: 9094050
Ann Clin Transl Neurol. 2016 Jul 25;3(9):684-94
pubmed: 27648458
Am J Cardiol. 2012 Feb 1;109(3):401-5
pubmed: 22078220
Neurology. 2006 Jun 13;66(11):1717-20
pubmed: 16769946
Mov Disord. 2009 Sep 15;24(12):1779-84
pubmed: 19562766
J Neurol Neurosurg Psychiatry. 2015 Jun;86(6):660-6
pubmed: 25112308
Mov Disord. 2005 Jul;20(7):777-82
pubmed: 15747359
Lancet Neurol. 2007 Oct;6(10):878-86
pubmed: 17826341
Mov Disord. 2005 Dec;20(12):1585-91
pubmed: 16114019
Neurology. 2006 Jun 13;66(11):1711-6
pubmed: 16769945
Ann Clin Transl Neurol. 2018 Nov 10;6(1):15-26
pubmed: 30656180
Ann Neurol. 2016 Mar;79(3):485-95
pubmed: 26704351
J Child Neurol. 2012 Sep;27(9):1223-9
pubmed: 22832776
Mov Disord. 2010 Mar 15;25(4):426-32
pubmed: 20063431
Neurodegener Dis Manag. 2018 Aug;8(4):233-242
pubmed: 30051753
Neurol Sci. 2016 Mar;37(3):361-4
pubmed: 26621361
Cerebellum. 2012 Jun;11(2):488-504
pubmed: 21964941
Arch Neurol. 2010 Aug;67(8):941-7
pubmed: 20697044
Neurology. 2018 Sep 4;91(10):e917-e930
pubmed: 30097477
Mov Disord. 2018 Jul;33(6):1000-1005
pubmed: 29624723
Health Technol Assess. 2009 Feb;13(12):iii, ix-x, 1-177
pubmed: 19216837
J Neurol. 2012 Feb;259(2):284-91
pubmed: 21779958